Back to Agenda
Session 3 - Naming, Labeling and Postmarketing Activities
Session Chair(s)
Sundar Ramanan, PhD
Director, Global Biosimilars R&D Policy
Amgen Inc., United States
Speaker(s)
Naming: A Global Perspective
Juergen Schmider, MD, PhD
Pfizer Inc., United States
Vice President, Pharmacovigilance & Safety Evaluation and Reporting
Naming: A Global Perspective
Geoff Eich
Amgen Biosimilars, United States
Executive Director, External Affairs
Labeling Product Information
Erika F. Lietzan, JD, MA
University of Missouri, United States
Associate Professor of Law
The WHO’s Perspective: Naming Guidance
Raffaella Giovanna Balocco Mattavelli, PharmD, PhD
World Health Organization (WHO), Switzerland
Group Lead, International Nonproprietary Name Programme
Pharmacy Practice
Gerald McEvoy, PharmD
American Society of Health-System Pharmacists, United States
Assistant Vice President of Drug Information
Pharmacovigilance and Risk Management
John D Ayres, JD, MD
Eli Lilly & Company Ltd., United States
Senior Director, Product Safety Assessments, Global Patient Safety
Panel Discussion
All Session Speakers, United States
Have an account?